Predictors of early response to infliximab in patients with ulcerative colitis. - Wikidata - awgldk - TriplyDB

Predictors of early response to infliximab in patients with ulcerative colitis.

Predictors of early response to infliximab in patients with ulcerative colitis.

http://www.wikidata.org/entity/Q51771485

about

Antibody markers in the diagnosis of inflammatory bowel disease Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis Therapeutic drug monitoring in inflammatory bowel disease Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis.CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitis Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis.European evidence-based Consensus on the management of ulcerative colitis: Current management.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Predicting response to Anti-TNF Agents for the treatment of crohn's disease.Quantification of biological network perturbations for mechanistic insight and diagnostics using two-layer causal models.Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years.IFNG rs1861494 polymorphism is associated with IBD disease severity and functional changes in both IFNG methylation and protein secretion.Current and future role of biomarkers in Crohn's disease risk assessment and treatment.Predictors of aggressive inflammatory bowel disease.C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study Therapeutic strategies for the management of ulcerative colitis.Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN.Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.Serological antibodies in inflammatory bowel disease: a systematic review.Current and future role of serogenomics in ulcerative colitis.The role of autoantibodies in inflammatory bowel disease.Circulating antibodies against bacterial wall products: are there arguments for early immunosuppression?Review article: strategies for the management of chronic unremitting ulcerative colitis.The positioning of colectomy in the treatment of ulcerative colitis in the era of biologic therapy.Towards personalized care in IBD.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis.The use of prognostic factors in inflammatory bowel diseases.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.Management of Inflammatory Bowel Disease in the Elderly.Cultured blood T-cell responses predict anti-TNF therapy response in patients with ulcerative colitis.The biologics of ulcerative colitis.Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.

P2860

Q26774452-B63706C8-453D-4EF1-89C9-CA0CF0AF2BBF Q26823221-9250AA7E-1164-4FA7-8937-4D0299F8E96C Q26852729-882EDA65-1A08-47C4-A5B1-D65EA45827BF Q28088683-8BB85429-1F24-4B20-B8E7-66363DEDAC79 Q33596959-8A07C87D-7D07-494D-B6BB-74AC2954340C Q33695285-0EBDB0AA-444E-4ADF-B278-D00CDBE1A2CB Q33927688-ED2402EB-0E55-45F2-834E-FDD63CF78C03 Q33948374-16496A9E-7CD1-4247-BACA-8B6418BF9E81 Q34025054-E9ADE724-B4CE-406C-9A19-5CDB62E83747 Q34147687-110B9888-811C-4257-98F9-C61A5E29D57C Q34408990-020741EA-850C-42F0-9ADB-C5EA49040E1E Q34486361-6A5276C6-0C74-4A18-8F51-49990B9B7F5A Q35026410-A8CBC837-33C2-4040-8983-762867763E06 Q35082666-A6812B97-6B73-4F63-9991-B0DE3DCA83E9 Q35095265-CDDC73EC-A621-4FAF-A22B-B2D8845F8D31 Q35691407-D9D3CF45-2270-49A2-A98C-755CAA15125D Q35745374-B7338839-DCF8-4A1B-9238-CD7859CA5058 Q37318035-5EB21B95-86B7-4A5A-82DA-78340AC04FF6 Q37522688-75EA6803-A6D8-4C85-858B-532244153421 Q37827687-F164B68D-793B-4FE9-8CC0-85BCA6813934 Q37860252-782A5060-C300-40B4-8682-A365C88B4AB8 Q37870433-0F906652-3987-46B7-9FB8-1B84998C2D33 Q37936394-73DD2056-9639-440B-97C6-8A5D0CD7BC4F Q37947158-55CF5E2D-6334-4DEC-BD26-F8B4BC253F16 Q37954231-56606A30-1B11-4426-B8C5-583E8D401865 Q37980742-4DA4C858-E953-49B4-A279-30D5F7964132 Q38020711-1F6007B2-C736-4147-B6E8-E87D49CFC9B3 Q38072225-9BEC0930-D045-4016-800F-01CBC1AA7288 Q38110317-131BEE79-B818-4289-BF63-9089E5769CD0 Q38121000-270920B3-6E2B-4881-98A0-87E35011B6B4 Q38171924-1159820B-F0D0-4A5A-B9A9-1D60A72DEC95 Q38176154-B362EAF9-5B2C-4C86-A15A-D7B852E71AD4 Q38184706-F81CD0F8-40A2-43A5-846F-926AAA001E73 Q38240881-B25E648D-58CC-43D5-B760-B589379C27A6 Q38254878-488630B1-7A59-49E8-8BF4-FE722D6C09B6 Q38501680-0F08141D-D98E-4CBA-B69F-AAAE39401305 Q38844393-99FDBBDE-90B1-467C-8300-4E6BCEE0B373 Q39019746-F6B671E6-287D-4A25-A856-5F67C5783EC1 Q39037681-B0DFF16A-6729-4EBD-92E8-F8F5452F2405 Q39116859-EEC01A0C-1D46-41F8-958F-A6CC651796AA

P2860

Predictors of early response to infliximab in patients with ulcerative colitis.

http://www.wikidata.org/entity/Q51771485

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Predictors of early response to infliximab in patients with ulcerative colitis.

@en

Predictors of early response to infliximab in patients with ulcerative colitis.

@nl

type

label

Predictors of early response to infliximab in patients with ulcerative colitis.

@en

Predictors of early response to infliximab in patients with ulcerative colitis.

@nl

prefLabel

Predictors of early response to infliximab in patients with ulcerative colitis.

@en

Predictors of early response to infliximab in patients with ulcerative colitis.

@nl

P1433

Q51771485-829CCC4A-4598-4B6D-818C-2F83A11975EC

P1476

Q51771485-EE2BF8DD-427E-415A-94F5-AC7850C6788D

P2093

Q51771485-42091339-1956-4C80-851A-EE2555273241

Q51771485-608A1322-7AAB-4FD7-A5A7-11DA935030B8

Q51771485-960ABAFC-3459-436F-BAF4-5EF6C86E0345

Q51771485-9C4BB00A-646D-4439-B0CA-A69A9D758978

Q51771485-A12B87C3-D57C-4B3A-8F09-7CA7A0CCC715

Q51771485-A4B673E6-7543-4DCF-9086-4098FE958689

Q51771485-CBFF3052-2339-4036-A654-7D6C330CCE0A

Q51771485-F6B8A3CB-A48D-4FE1-92CF-8457E6EACD92

P2860

Q51771485-0CC40819-E600-419E-9FDA-E14B6E42F2F0

Q51771485-17795F7E-45C8-4C0C-8B2F-667D3F8B53B6

Q51771485-17F9A616-4CBA-48AF-92D2-C390F5C490B8

Q51771485-29595CFA-30CF-4BE5-8335-34F0D221342E

Q51771485-4A4AF322-009D-49AE-A4A3-8A377C1B8E91

Q51771485-55D5DA43-3160-4056-BFFF-5210D39A4931

Q51771485-73A755A0-BFD5-47D1-B697-CB0D15C2A50C

Q51771485-782B9355-1261-4EF0-9348-817B91865C03

Q51771485-85A198B2-4C9B-454B-A836-1D5A10C64BBA

Q51771485-8F123EF2-1D61-4B89-BAC9-27716070534F

P304

Q51771485-7608EFC6-4F4C-468E-9B9D-BCAA58D77677

P31

Q51771485-A99CFA52-1E14-4AFB-A053-E9E2E7AD7E2E

P356

Q51771485-E9F88BDC-01AF-41FA-93BD-2B206B78EA27

P433

Q51771485-DE5D399A-C1C9-4C95-A75C-DCEB51644B76

P478

Q51771485-F46638E4-7906-4B29-BDF6-2086F22AADD7

P50

Q51771485-130E40F3-9C4C-4DD2-A9C7-C60C055C7065

Q51771485-3A41C145-B88A-484A-9AA0-170631D1D801

Q51771485-58B2E815-1460-4623-BC05-3152484252BB

P577

Q51771485-2762B9FC-9FFD-418B-8AEB-A30E9DC18DD9

P5875

Q51771485-7F71F10D-7825-45E4-A0E4-31964177D991

P698

Q51771485-D91AA039-76B8-4040-B021-6A81062D63C0

P356

P1433

Inflammatory Bowel Diseases

P1476

Predictors of early response to infliximab in patients with ulcerative colitis.

@en

P2093

Fabian Schnitzler

http://www.w3.org/2001/XMLSchema#string

Gert De Hertogh

http://www.w3.org/2001/XMLSchema#string

Ilse Hoffman

http://www.w3.org/2001/XMLSchema#string

Ingrid Arijs

http://www.w3.org/2001/XMLSchema#string

J Karel Geboes

http://www.w3.org/2001/XMLSchema#string

Konstantinos H Katsanos

http://www.w3.org/2001/XMLSchema#string

Maja Noman

http://www.w3.org/2001/XMLSchema#string

Marc Ferrante

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Infliximab for induction and maintenance therapy for ulcerative colitis

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Cyclosporine in severe ulcerative colitis refractory to steroid therapy.

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

Medical therapy for ulcerative colitis 2004.

Are there predictors of Remicade treatment success or failure?

Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis.

Predictors of response to infliximab in patients with Crohn's disease.

A reproducible grading scale for histological assessment of inflammation in ulcerative colitis.

P304

123-128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IBD.20054

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Séverine Vermeire

Gert Van Assche

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6593933

http://www.w3.org/2001/XMLSchema#string

P698

17206703

http://www.w3.org/2001/XMLSchema#string